Newswire (Published: Tuesday, April 11, 2017, Received: Friday, April 7, 2017, 4:32:19 PM CDT)

Word Count: 463

By a News Reporter-Staff News Editor at Cancer Weekly -- - Genomic Health, Inc. (Nasdaq: GHDX) announced the presentation of new results from a large multi-center validation study, which confirmed that the Oncotype DX® Genomic Prostate Score™ (GPS) is a strong independent predictor of metastases at 10 years in prostate cancer patients across all National Comprehensive Cancer Network (NCCN) clinical risk groups. The clinical validation study data were designated one of the "best posters" (abstract #352) at the HYPERLINK "" \n32nd Annual European Association of Urology (EAU) Congress in London (see also Genomic Health, Inc.).

"Now validated for all major near- and late-term endpoints of adverse pathology, biochemical recurrence, metastasis and prostate cancer-specific death, Oncotype DX becomes the only genomic test to provide physicians with an assessment of both the current state and future risk of their patient's cancer based on biology to help them confidently decide between active surveillance or surgery," said Phil Febbo, M.D., chief medical officer, Genomic Health. "We believe the breadth of clinical evidence from 22 studies in more than 4,200 patients further supports the test's broader adoption in the U.S."

Researchers evaluated biopsy tissue from 259 patients in Kaiser Permanente'sNorthern California region, identified from a database of men treated with radical prostatectomy and diagnosed with low-, intermediate- or high-risk prostate cancer. The majority of patients (67%) included in this study had intermediate-risk disease.

Results showed a range of 10-year risk within each NCCN risk group and confirmed that the GPS was strongly associated with metastases (p<0.001) in multivariable analysis when compared to other risk criteria and provided additional independent information about tumor aggressiveness and long-term outcomes. An additional key finding was that that no patients with low- or intermediate-risk prostate cancer and a GPS result of less than 20 developed metastatic disease following radical prostatectomy.

"It is important to seek ways to better understand how to tell a man with newly diagnosed prostate cancer what his risk of developing metastatic disease or dying of the disease is," said Stephen Van Den Eeden, Ph.D., Kaiser Permanente Division of Research, Oakland, Calif. "Our study suggests that this test may help some men and their physicians make better decisions on whether to pursue active surveillance or receive definitive treatment."

Additional results from this clinical validation study using Kaiser Permanente data, which also analyzed the GPS performance in predicting prostate cancer-specific mortality in patients with early-stage disease, have been accepted for presentation at the American Urological Association 2017 Annual Meeting in May.

Keywords for this news article include: Genetics, Oncology, Epidemiology, Genomic Health Inc., Prostatic Neoplasms, Risk and Prevention, Diagnostics and Screening, Metastatic Prostate Cancer.

Our reports deliver fact-based news of research and discoveries from around the world. Copyright 2017, NewsRx LLC


Genomic Health Inc.
Kaiser Permanente International


North America
Northern Europe
United Kingdom
United States


Science and Technology
      Scientific Research
Health and Wellness
      Medical Conditions and Diseases
                  Prostate Cancer
            Men's Health Issues
                  Prostate Cancer
            Urological Diseases
      Health Sciences
            Medical Research
      Medical Specialties and Practices